Israel Englander Cytom X Therapeutics, Inc. Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 671,628 shares of CTMX stock, worth $819,386. This represents 0.0% of its overall portfolio holdings.

Number of Shares

671,628

Previous 794,047 15.42%

Holding current value

$819,386

Previous $1.23 Million 19.02%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.41 - $2.74 $172,610 - $335,428	-122,419 Reduced 15.42%	671,628 $1.46 Million
Q4 2023 Feb 14, 2024	BUY	$1.07 - $1.55 $154,881 - $224,360	144,749 Added 22.29%	794,047 $1.23 Million
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $439,559 - $598,548	-311,744 Reduced 32.44%	649,298 $1.12 Million
Q1 2023 May 15, 2023	SELL	$1.48 - $2.88 $1.12 Million - $2.19 Million	-758,769 Reduced 44.12%	961,042 $1.45 Million
Q4 2022 Feb 14, 2023	BUY	$1.19 - $1.91 $1.41 Million - $2.27 Million	1,187,298 Added 222.96%	1,719,811 $2.75 Million

Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $1.12 Million - $1.79 Million	-909,219 Reduced 63.06%	532,513 $772,000
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $1.23 Million - $2.32 Million	-803,458 Reduced 35.79%	1,441,732 $2.64 Million
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $2.61 Million - $4.58 Million	978,268 Added 77.22%	2,245,190 $6 Million
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $1.28 Million - $2.44 Million	330,074 Added 35.23%	1,266,922 $5.49 Million
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $1.47 Million - $2.19 Million	340,519 Added 57.1%	936,848 $4.77 Million
Q2 2021 Aug 16, 2021	BUY	$6.33 - $9.91 $779,140 - $1.22 Million	123,087 Added 26.01%	596,329 $3.78 Million
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $729,834 - $995,229	110,581 Added 30.49%	473,242 $3.66 Million
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $427,324 - $521,771	66,047 Added 22.27%	362,661 $2.38 Million
Q3 2020 Nov 16, 2020	BUY	$6.55 - $8.83 $1.25 Million - $1.68 Million	190,592 Added 179.77%	296,614 $1.97 Million
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $1.39 Million - $2.76 Million	-188,291 Reduced 63.98%	106,022 $883,000
Q1 2020 May 14, 2020	SELL	$3.61 - $8.6 $107,105 - $255,153	-29,669 Reduced 9.16%	294,313 $2.26 Million
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $1.35 Million - $2.32 Million	260,709 Added 412.04%	323,982 $2.69 Million
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $3.04 Million - $5.04 Million	-411,565 Reduced 86.67%	63,273 $466,000
Q2 2019 Aug 15, 2019	BUY	$9.35 - $11.41 $3.86 Million - $4.71 Million	412,404 Added 660.54%	474,838 $5.33 Million
Q2 2019 Aug 14, 2019	SELL	$9.35 - $11.41 $257,153 - $313,809	-27,503 Reduced 30.58%	62,434 $3.72 Million
Q1 2019 May 14, 2019	SELL	$9.5 - $19.16 $650,759 - $1.31 Million	-68,501 Reduced 43.24%	89,937 $967,000
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $749,382 - $1.1 Million	-59,053 Reduced 27.15%	158,438 $2.39 Million
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $855,637 - $1.25 Million	-47,430 Reduced 17.9%	217,491 $4.02 Million
Q2 2018 Aug 14, 2018	SELL	$21.38 - $29.68 $7.05 Million - $9.79 Million	-329,867 Reduced 55.46%	264,921 $6.06 Million
Q1 2018 May 15, 2018	SELL	$21.76 - $34.22 $5.28 Million - $8.3 Million	-242,627 Reduced 28.97%	594,788 $16.9 Million
Q4 2017 Feb 14, 2018	BUY	$19.0 - $23.09 $4.04 Million - $4.9 Million	212,423 Added 33.99%	837,415 $17.7 Million
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $8.46 Million - $11.4 Million	624,992	624,992 $11.4 Million

Others Institutions Holding CTMX

# of Institutions

Shares Held

43.9M

Call Options Held

105K

Put Options Held

4.5K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $80.5M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account